N/A
N=10
Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease
End-Stage Renal Disease
Bottom Line
View on ClinicalTrials.gov: NCT00677534 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcome: Primary: Change in Monocyte VDR Expression With Vitamin D Therapy — 1899 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Cholecalciferol (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of Kansas
- Primary completion
- Aug 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Monocyte VDR Expression With Vitamin D Therapy |
1899 | — |
Summary
The goal of this study is to evaluate the role of nutritional Vitamin D deficiency as a potential contributor to the morbidity witnessed in patients with end-stage renal disease
Eligibility Criteria
Inclusion Criteria
- End-stage renal disease undergoing maintenance hemodialysis at KUMC outpatient hemodialysis unit
- Dialysis vintage of at least 6 months duration
- Nutritional vitamin D deficiency, defined as 25(OH)D 500)
- History of chronic inflammatory disease process, such as inflammatory bowel, rheumatoid arthritis, lupus, etc.
- Cinacalcet therapy
- Previous allergy to ergocalciferol
- History of parathyroidectomy
- Current treatment with immunosuppressant medications
- Noncompliance with prescribed hemodialysis regimen (i.e. skipping treatments, ending sessions early)
- Functional renal transplant within the last five years
Data sourced from ClinicalTrials.gov (NCT00677534). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.